| ‣ |
Tamoxifen, Aromatase inhibitors, Leuprolide |
Block hormone signaling driving tumor growth |
Not cell-cycle specific |
Hot flashes, thromboembolism, osteoporosis |
Common in breast and prostate cancer |
| ‣ |
Imatinib, Erlotinib, Trastuzumab |
Block specific molecular targets |
Variable |
Depends on target |
Less nonspecific toxicity than classic chemo |
| ‣ |
Pembrolizumab, Nivolumab, Ipilimumab |
Activate immune system against cancer |
Not cell-cycle specific |
Autoimmune/inflammatory toxicities |
Immune checkpoint inhibitors |
| ‣ |
|
|
|
|
|